The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant (Q45216949)

10 December 2017

title

The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant (English)

1 reference

10 December 2017

0 references

6

Arnaldo Caruso

1 reference

10 December 2017

Pablo D Becker

1

1 reference

10 December 2017

Simona Fiorentini

2

1 reference

10 December 2017

Claudia Link

3

1 reference

10 December 2017

Giorgio Tosti

4

1 reference

10 December 2017

Thomas Ebensen

5

1 reference

10 December 2017

Carlos A Guzmán

7

1 reference

10 December 2017

language of work or name

English

0 references

publication date

21 November 2005

1 reference

10 December 2017

number of pages

8

1 reference

inferred from page(s)

published in

Vaccine

1 reference

10 December 2017

volume

24

1 reference

10 December 2017

issue

25

1 reference

10 December 2017

page(s)

5269-5276

1 reference

Prospects for vaccine protection against HIV-1 infection and AIDS.

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

HIV-1 Tat protein trans-activates transcription in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

HIV-1 matrix protein p17 resides in cell nuclei in association with genomic RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

HIV p17 enhances lymphocyte proliferation and HIV-1 replication after binding to a human serum factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

Characterization of a B220+ Lymphoid Cell Subpopulation with Immune Modulatory Functions in Nasal-Associated Lymphoid Tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

The role of helper T cell products in mouse B cell differentiation and isotype regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

Towards an HIV-1 vaccine: lessons from studies in macaque models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

Live attenuated HIV vaccines: pitfalls and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

Public health. AIDS vaccine still alive as booster after second failure in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

Biological markers associated with prolonged survival in African children maternally infected by the human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

7 January 2021

Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

7 January 2021

A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

7 January 2021

Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

7 January 2021

Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.008

7 January 2021

10.1016/J.VACCINE.2005.11.008

Identifiers

DOI

1 reference

10 December 2017

1 reference